Chemical and Physical Characterizations of Potential New Chemical Entity

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Volumn , Issue , 2008, Pages 211-225

  Adeniji, Adegoke ^a   Adejare, Adeboye ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Gas chromatography (GC) and high performance liquid chromatography (HPLC); Mass spectrometry (MS) and elemental analysis; New chemical entity (NCE)

Indexed keywords

EID: 77953393823     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch6     Document Type: Chapter

References (39)

1. http://www.fda.gov/cder/about/smallbiz/exclusivity.htm.
2. Bradley D. High(throughput) mass. Modern Drug Discov 2003;6(4):43-45.
3. Tufts Centre for the Study of Drug Development. Backgrounder:how new drugs move through the development and approval process, 2001. http://csdd.tufts.edu/NewsEvents/ RecentNews.asp?newsid=4.
4. Martin A. Physical pharmacy, 4th ed. Philadelphia:Lea & Febiger; 1993, Ch 4, pp 77-78.
5. Dewitte RS, Kolovanov E. Pharmaceutical Profiling in Drug Discovery for Lead Selection. Arlington, VA:AAPS Press;PUBX; 2004, Vol 1, Ch 2, pp 27-28.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:4-25.
7. Lipinski CA. Drug like properties and the cause of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-249.
8. Gupta PK. Solutions and phase equilibra. In Remington:The Science and Practice of Pharmacy, 21st ed. Baltimore:Lippincott Williams & Wilkins; 2005, Ch 16, pp 224-228.
9. Skoog DA, Holler FJ, Nieman TA. Principles of Instrumental Analysis, 5th ed. Belmont, CA:Brooks/Cole and Thomson Learning; 1998, Ch 33, pp 524-528.
10. Chaudhry AK, Singh GS, Stephenson GA, Ackermann BL. Instrumental methods of analysis. In Remington:The Science and Practice of Pharmacy, 21st ed. Baltimore:Lippincott Williams & Wilkins; 2005, Ch 34, pp 633-636.
11. Skoog DA, Holler FJ, Nieman TA. Principles of Instrumental Analysis, 5th ed. Belmont, CA:Brooks/Cole and Thomson Learning; 1998, Ch 33, pp 844-845.
12. Zimmerman JJ, Feldman S. Physical-chemical properties and biological activity. In William Foye's Principles of Medicinal Chemistry, 2nd ed. Philadelphia:Lea & Febiger; 1981, Ch 2, pp 39-40.
13. Verkman AS. Drug discovery in academia. Am J Physiol Cell Physiol 2004;286:C465-C474.
14. Chaudhry AK, Singh GS, Stephenson GA, Ackermann BL. Instrumental methods of analysis. In Remington:The Science and Practice of Pharmacy, 21st ed. Baltimore:Lippincott Williams & Wilkins; 2005, Ch 34, pp 635-640.
15. Dalvit C, Fagerness PE, Hadden DTA, Sarver RW, Stockman BJ. Fluorine-NMR experiments for high-throughput screening:theoretical aspects, practical considerations, and range of applicability. J Am Chem Soc 2003;125(25):7696-7703.
16. 31 P solid state NMR studies of the structure of amine-intercalated a-zirconium phosphate. 2. Titration of a-zirconium phosphate with n-propylamine and n-butylamine. J Phys Chem 1992;96:3458-3464.
17. Eaton DC. Laboratory Investigations in Organic Chemistry. New York:McGraw-Hill; 1989, Experiment 2, pp 65-67.
18. Skoog DA, Holler FJ, Nieman TA. Principles of Instrumental Analysis, 5th ed. Belmont, CA:Brooks/Cole and Thomson Learning; 1998, Ch 26, pp 674-677.
19. Nopper B, Kohen F, Wilchek M. A thiophilic adsorbent for the one-step high performance liquid chromatography purification of monoclonal antibodies. Anal Biochem 1989;180(1):66-71.
20. Permuleter JS, Loftin S, Carl JL, Karimi. M. Modified high-performance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenylacetic acid. J Chromatogr B 2006;836:120-123.
21. Axe BP. Trace level detection and quantification of ethyl-diazoacetate by reverse phase high performance liquid chromatography and UV detection. J Pharm Biomed Anal 2006;41:804-810.
22. Saito M, Morris S, Yomota C, Iwaya K, Kudo K. Determination of enantiomeric purity of hyoscyamine from scopolia extract using HPLC-CD without chiral separation. Enantiomer 2000;5(3-4):369-375.
23. Adejare A, Deal SA, Day MS. Syntheses and β-adrenergic binding affinities of (R)-and (S)-fluoronaphthyloxypropanolamines. Chirality 1999;11:144-148.
24. Lipinski CA. Avoiding investment in doomed drugs. Curr Drug Discov 2001;Apr:17-19.
25. a in drug bioavailability:estimation of solubility, permeability, absorption and bioavailability. In Methods and Principles in Medicinal Chemistry, Volume 18. Weinheim:Wiley-VCH; 2003, Ch 2, pp 21-45.
26. Di. L, Kerns EH. Pharmaceutical profiling in drug discovery. Drug Discov Today 2003;8(7):316-323.
27. Chui, W-K, Tsun-Hon Wong P, Thenmozhiyal JC. Anticonvulsant activity of phenylmethylenehydantoins:a structure-activity relationship study. J Med Chem 2004;47:1527-1535.
28. Kurz H, Hofstetter A, Teschemacher H, Herz A, The importance of lipid-solubility for the central action of cholinolytic drugs. Neuropharmacology 1965;4(4):207-218.
29. Xu XH, Song JZ, Qaio CF, Tai J, Cheung S, Han QB. Stability and cytotoxicity of gambogic acid and its derivative gambogoic acid. Biol Pharm Bull 2005;28(12):2335-2337.
30. Trissel LA, Zhang Y, Xu Q. Physical and chemical stability of gemcitabine hydrochloride solutions. J Am Pharm Assoc 1999;39(4):509-513.
31. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature 2004;432:855-861.
32. Kirkpatrick P, Lebbos J, LaBonte J. Fresh from the pipeline:enfuvirtide. N at Rev Drug Discov 2003;2:345-346.
33. Gefter ML, Wallner BP. Peptide treatment for allergic diseases. C lin Immunol Immunopathol 1996;80(2):105-109.
34. Adejare A, Brown PW. Hydrogen/deuterium exchange to differentiate fragments ions from pseudomolecular ions by electrospray tandem mass spectrometry. Anal Chem 1997;69(8):1525-1529.
35. Skoog DA, Holler FJ, Nieman TA. Principles of Instrumental Analysis, 5th ed. Belmont, CA:Brooks/Cole and Thomson Learning; 1998, Ch 31, pp 805-808.
36. Martin A. Physical Pharmacy, 4th ed. Philadelphia:Lea & Febiger; 1993, Ch 2, pp 46-48.
37. Wells RM. Design and synthesis of non-peptide rigid sulfonamide gamma secretase inhibitors. MS thesis, Idaho State University, 2003.
38. Adejare A, El-Gendy AM. Membrane permeability related physicochemical properties of a novel γ-secretase inhibitor. Int J Pharm 2004;280:45-55.
39. Adejare A, Sciberras SS. Syntheses and β-adrenergic activities of(R)-fluoronaphthyloxypropanolomaine. Pharm Res 1997;14(4):533-536.